Clinical Trial Update: CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia [Phase 2]

View source ↗

Summary

Phase 2 trial of lenalidomide plus rituximab in Waldenström's macroglobulinemia was terminated; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Waldenström Macroglobulinemia

Drugs mentioned

• Revlimid (lenalidomide)
• Rituxan (rituximab)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Waldenstrom's Macroglobulinemia | Phase 2 | Status: TERMINATED | Results posted: 2015-12-16